Bavencio Seen as Ineffective in Phase 3 Head and Neck Cancer Trial

A Phase 3 trial of Bavencio (avelumab) in people with squamous cell carcinoma of the head and neck (SCCHN) was ended early due to a lack of effectiveness seen in an interim analysis, the companies that developed and are marketing the treatment announced. Data from the study, named JAVELIN Head and Neck 1oo (NCT02952586), showed that Bavencio failed to provide significant benefits in the primary measurement of efficacy — progression free survival — the amount of time patients…

You must be logged in to read/download the full post.